Browse > Article
http://dx.doi.org/10.5487/TR.2018.34.2.151

Anti-Diabetic Effects of Dung Beetle Glycosaminoglycan on db Mice and Gene Expression Profiling  

Ahn, Mi Young (Department of Agricultural Biology, National Academy of Agricultural Science, RDA)
Kim, Ban Ji (Department of Agricultural Biology, National Academy of Agricultural Science, RDA)
Yoon, Hyung Joo (Department of Agricultural Biology, National Academy of Agricultural Science, RDA)
Hwang, Jae Sam (Department of Agricultural Biology, National Academy of Agricultural Science, RDA)
Park, Kun-Koo (Pharmacogenechips Inc.)
Publication Information
Toxicological Research / v.34, no.2, 2018 , pp. 151-162 More about this Journal
Abstract
Anti-diabetes activity of Catharsius molossus (Ca, a type of dung beetle) glycosaminoglycan (G) was evaluated to reduce glucose, creatinine kinase, triglyceride and free fatty acid levels in db mice. Diabetic mice in six groups were administrated intraperitoneally: Db heterozygous (Normal), Db homozygous (CON), Heuchys sanguinea glycosaminoglycan (HEG, 5 mg/kg), dung beetle glycosaminoglycan (CaG, 5 mg/kg), bumblebee (Bombus ignitus) queen glycosaminoglycan (IQG, 5 mg/kg) and metformin (10 mg/kg), for 1 month. Biochemical analyses in the serum were evaluated to determine their anti-diabetic and anti-inflammatory actions in db mice after 1 month treatment with HEG, CaG or IQG treatments. Blood glucose level was decreased by treatment with CaG. CaG produced significant anti-diabetic actions by inhiting creatinine kinase and alkaline phosphatase levels. As diabetic parameters, serum glucose level, total cholesterol and triglyceride were significantly decreased in CaG5-treated group compared to the controls. Dung beetle glycosaminoglycan, compared to the control, could be a potential therapeutic agent with anti-diabetic activity in diabetic mice. CaG5-treated group, compared to the control, showed the up-regulation of 48 genes including mitochondrial yen coded tRNA lysine (mt-TK), cytochrome P450, family 8/2, subfamily b, polypeptide 1 (Cyp8b1), and down-regulation of 79 genes including S100 calcium binding protein A9 (S100a9) and immunoglobulin kappa chain complex (Igk), and 3-hydroxy-3-methylglutaryl-CoenzymeAsynthase1 (Hmgcs1). Moreover, mitochondrial thymidine kinase (mt-TK), was up-regulated, and calgranulin A (S100a9) were down-regulated by CaG5 treatment, indicating a potential therapeutic use for anti-diabetic agent.
Keywords
Anti-diabetic effect; Queen of B. ignitus; Catharsius molossus; Glycosaminoglycan; Microarray;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ahn, M.Y., Kim, B.J., Kim, H.J., Yoon, H.J., Jee, S.D., Hwang, J.S. and Park, K.K. (2017). Anti-obesity effect of Bombus ignitus queen glycosaminoglycans in rats on a highfat diet. Int. J. Mol. Sci., 18, E681.   DOI
2 Ahn, M.Y., Kim, B.J., Kim, H.J., Hwang, J.S., Jung, Y.S. and Park, K.K. (2017) Anti-aging effect and gene expression profiling of dung beetle glycosaminoglycan in aged rats. Biomater. Res., 21, 5.   DOI
3 Xia, L., Bai, L., Yi, L., Liu, B., Chu, C., Liang, Z., Li, P., Jiang, Z. and Zhao, Z. (2007) Authentication of the 31 species of toxic and potent chinese materia medica (T/PCMM) by microscopic technique, part 1: three kinds of toxic and potent animal CMM. Microsc. Res. Tech., 70, 960-968.   DOI
4 Kim, Y.S., Jo, Y.Y., Chang, I.M., Toida, T., Park, Y. and Linhardt, R.J. (1996) A new glycosaminoglycan from the giant african snail Achatina fulica. J. Biol. Chem. 271, 11750-11755.   DOI
5 Fratz, E.J., Hunter, G.A. and Ferreira, G.C. (2014) Expression of murine 5-aminolevulinate synthase variants causes protoporphyrin IX accumulation and light-induced mammalian cell death. PLoS ONE, 9, e93078.   DOI
6 Song, J., Liu, H., Ressom, H.W., Tiwari, S. and Ecelbarger, C.M. (2008) Chronic Rosigiltazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese Zucker rats as determined by microarray by microarray analysis. Exp. Clin. Endocrinol. Diabetes, 116, 315-325.   DOI
7 Kraakman, M.J., Lee, M.K.S., Al-Sharea, A., Dragoljevic, D., Barrett, T.J., Montenont, E., Basu, D., Heywood, S., Kammoun, H.L., Flynn, M., Whillas, A., Hanssen, N.M.J., Febbraio, M.A., Westein, E., Fisher, E.A., Chin-Dusting, J., Cooper, M.E., Berger, J.S., Goldberg, I.J., Nagareddy, P.R. and Murphy, A.J. (2017) Neutrophil-derived S100 calciumbinding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. J. Clin. Invest., 127, 2133-2147.   DOI
8 Giudicelli, V., Chaume, D. and Lefranc, M. (2005) IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res., 33, D256-D261.
9 Zhou, H. and Rigoutsos, I. (2014) The emerging roles of GPRC5A in diseases. Oncoscience, 1, 765-776.   DOI
10 Tanaka, T., Kubota, M., Shinohara, K., Yasuda, K. and Kato, J. (2003) In vivo analysis of the cyclin D1 promotor during early embryogenesis in Xenopus. Cell Struct. Funct., 28, 165-177.   DOI
11 Chowdhury, K.H., Montgomery, M.K., Morris, M.J., Cognard, E., Shepherd, R.R. and Smith, G.C. (2015) Glucagon phosphorylate serine 552 of beta-catenin leading to increased expression of cyclinD1 and C-Myc in isolated rat liver. Arch. Physiol. Biochem., 121, 88-96.   DOI
12 Lauver, D.A. and Lucchesi, B.R. (2006) Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc. Drug Rev., 24, 214-226.   DOI
13 Li, R., Xing, J., Mu, X., Wang, H., Zhang, L., Zhao, Y. and Zhang, Y. (2015) Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des. Devel. Ther., 9, 6275-6283.
14 Wang, F., Wan, A. and Rodrigues, B. (2013) The function of heparanase in diabetes and its complications. Can. J. Diabetes, 37, 332-338.   DOI
15 Ahn, M.Y., Hwang, J.S., Yoon, H.J. and Yun, E.Y. (2012) Anti-diabetic composition comprising glycosaminoglycans derived insect. Korean patient 10-120419.
16 Yan, W., Zhou, B., Shen, Y. and Xu, G. (2015) Antioxidant and antithrombotic therapies for diabetic kidney disease. Iran. J. Kidney Dis., 9, 413-420.
17 Lepedda, A.J., Muro, P.D., Capobianco, G. and Formato, M. (2017) Significance of urinary glycosaminoglycans/proteoglycans in the evaluation of type 1 and type 2 diabetes complications. J. Diabetes Complicat., 31, 149-155.   DOI
18 Kubaski, F., Osago, H., Mason, R.W., Yamaguchi, S., Kobayashi, H., Tsuchiya, M., Orii, T. and Tomatsu, S. (2017) Glycosaminoglycans detection methods: application of mass spectrometry. Mol. Genet. Metab., 120, 67-77.   DOI
19 Dou, J., Ma, J., Liu J., Wang, C., Johnsson, E., Yao, H., Zhao, J. and Pan, C. (2018) Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: results from the START study, a multicenter, randomized, double-blind, active-controlled, phase 3 trial. Diabetes Obes. Metab., 20, 590-598.   DOI
20 Heishi, M., Ichihara, J., Teramoto, R., Itakura, Y., Hayashi, K., Ishikawa, H., Gomi, H., Sakai, J., Kanaoka, M., Taiji, M. and Kimura, T. (2006) Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin. Diabetologia, 49, 1647-1655.   DOI
21 Mata, M.D.I., Garrido-Maraver, J., Cotan, D., Cordero, M.D., Oropesa-Avila, M., Izquierdo, L.G., Miguel, M.D., Lorite, J.B., Infante, E.R., Ybot, P., Jackson, S. and Sanchez-Alcazar, J.A. (2012) Recovery of MERRF fibroblasts and cybrids pathophysiology by Coenzyme Q10. Neurotherapeutics, 9, 446-463.   DOI
22 Ishida, H., Yamashita, C., Kuruta, Y., Yoshida, Y. and Noshiro, M. (2000) Insulin is a dominant suppressor of sterol 12a-hydroxylase P450 (CYP8B) expression in rat liver possible role of insulin in Circadian rhythm of CYP8B. J. Biochem., 127, 57-64.   DOI
23 Kaur, A., Patankar, J.V., de Haan, W., Ruddle, P., Wijesekara, N., Groen, A.K., Verchere, C.B., Singaraja, R.R. and Hayden, M.R. (2015) Loss of cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes, 64, 1168-1179.   DOI
24 Mortensen, O.H., Nielsen, A.R., Erikstrup, C., Plomgaard, P., Fischer, C.P., Krogh-Madsen, R., Lindegaard, B., Petersen, A.M., Taudorf, S. and Pedersen, B.K. (2009) Calprotectin - a novel marker of obesity. PLoS ONE, 4, e7419.   DOI